- $218.81bn
- $245.15bn
- $54.07bn
- 98
- 40
- 87
- 88
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval for AEGEAN
AnnouncementREG - AstraZeneca PLC - Enhertu recommended in EU in post-ET breast cancer
AnnouncementREG - AstraZeneca PLC - Camizestrant improved PFS in 1L HR+ breast cancer
AnnouncementREG - Redx Pharma Limited - Phase 1 Data on RXC008 Presented at ECCO
AnnouncementREG - AstraZeneca PLC - Filing of Form 20-F with SEC
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Annual Financial Report
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Final Results
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Imfinzi recommended for EU approval for LS-SCLC
AnnouncementREG - AstraZeneca PLC - Enhertu approved in US for breast cancer post ET
AnnouncementREG - AstraZeneca PLC - Dato-DXd approved in US for HR+ breast cancer
AnnouncementREG - AstraZeneca PLC - Calquence combination approved in US for 1L MCL
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd NSQ NSCLC application withdrawn in EU
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in EU based on LAURA trial
AnnouncementREG - AstraZeneca PLC - Directorate Change
Announcement